Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315

Daniel R. Kuritzkes, Anne Sevin, Benjamin Young, Minoo Bakhtiari, Hulin Wu, Marty St. Clair, Elizabeth Connick, Alan Landay, John Spritzler, Harold Kessler, Michael M. Lederman

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

The effect of baseline drug resistance mutations on response to zidovudine, lamivudine, and ritonavir was evaluated in zidovudine- experienced persons infected with human immunodeficiency virus type 1 (HIV- 1). Presence of the K70R mutation was associated with significantly higher plasma HIV-1 RNA levels at baseline. However, presence of resistance mutations did not affect the increase in plasma HIV-1 RNA during a 5-week drug washout, nor was there any effect on first-phase virus decay rates after initiation of therapy or on the probability of having plasma HIV-1 RNA levels <100 copies/mL at week 48. Polymorphisms at protease codons 10, 36, and 71 were associated with significantly faster second-phase decay rates. Suppression of plasma HIV-1 RNA despite presence of zidovudine resistance mutations implies that the presence of these mutations does not preclude a durable response to treatment with a potent 3-drug regimen.

Original languageEnglish (US)
Pages (from-to)491-497
Number of pages7
JournalJournal of Infectious Diseases
Volume181
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315'. Together they form a unique fingerprint.

Cite this